EBV EBNA3A (379-387) (HLA-B7) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV)
See full description
Liechti and Roederer (2019). OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. PMID: 31334913
Zhang et al (2012). How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses. PMID: 23202497
Cohen (2015). Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol. PMID: 26424649
Allday et al (2015). The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells. Curr Top Microbiol Immunol. PMID: 26428372
EBV EBNA3A (379-387) (HLA-B7) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and the consequent death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV EBNA3A (379-387) (HLA-B7) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B7 refers to the cell HLA type that this peptide acts on.
The Epstein-Barr nuclear antigen 3A (EBNA3A) protein plays a significant role in reprogramming the gene expression of host cells. The action of this protein affects cell proliferation, survival, differentiation and immune surveillance. EBNA3A also targets tumour suppressor pathways in the infected B cells, meaning it is considered an oncoprotein.
Search our datasheets by catalogue number, peptide sequence or name.
Discover more about how we can support you and our products.
Find answers to common queries about our products and company.
Cambridge Research Biochemicals 17-18 Belasis Court, Belasis Hall Technology Park Billingham TS23 4AZ
t +44 01642 567 183